WHAT IS CLAIMED IS:

1. A PD-L1 bicyclic peptide mimetic comprising a polypeptide that comprises at least three cysteine residues, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the PD-L1 bicyclic peptide mimetic comprises an amino acid sequence of:

$X_1C_1LX_2X_3IFC_2X_4LRKGX_5C_3X_6X_7X_8X_9KX_{10}$

or a modified derivative, or pharmaceutically acceptable salt, thereof;

wherein:

C_1, C_2, and C_3 represent first, second and third cysteine residues, respectively;

X_1 is absent or alanine;

X_2 is selected from any small amino acid (optionally, threonine, glycine, serine, or alanine, and preferably threonine or alanine, and most preferably, threonine);

X_3 is selected from any amino acid (preferably phenylalanine or alanine, and most preferably, phenylalanine);

X_4 is selected from any amino acid (preferably arginine or alanine, and most preferably, arginine);

X_5 is selected from any amino acid (preferably arginine or alanine, and most preferably, arginine);

X_6 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, leucine, proline, glycine, isoleucine, phenylalanine, tryptophan, valine, ~~and~~ or norleucine; preferably methionine, alanine, leucine, or proline; and most preferably, methionine);

X_7 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, proline, leucine, glycine, isoleucine, phenylalanine, tryptophan, valine, ~~and~~ or norleucine; preferably methionine, alanine or proline; and most preferably, methionine or alanine);

X_8 is selected from any amino acid (preferably, aspartic acid, alanine, glycine, or valine; and most preferably, aspartic acid);

X_9 is selected from any nonpolar/neutral amino acid (e.g., valine, alanine, glycine, methionine, leucine, proline, isoleucine, phenylalanine, tryptophan, ~~and~~or norleucine; preferably valine, alanine, glycine or methionine; and most preferably valine); and

X_{10} is selected from any amino acid (preferably lysine, alanine, asparagine, or methionine; and most preferably, lysine).

~~2. The PD-L1 bicyclic peptide mimetic of claim 1, wherein X_2 is selected from threonine and alanine.~~

~~3. The PD-L1 bicyclic peptide mimetic of claim 1 or claim 2, wherein X_2 is threonine.~~

~~4. The PD-L1 bicyclic peptide mimetic of any one of claims 1-3, wherein X_3 is selected from phenylalanine and alanine.~~

~~5. The PD-L1 bicyclic peptide mimetic of any one of claims 1-4, wherein X_3 is phenylalanine.~~

~~6. The PD-L1 bicyclic peptide mimetic of any one of claims 1-5, wherein X_4 is selected from arginine and alanine.~~

~~7. The PD-L1 bicyclic peptide mimetic of any one of claims 1-6, wherein X_4 is arginine.~~

~~8. The PD-L1 bicyclic peptide mimetic of any one of claims 1-7, wherein X_5 is selected from arginine and alanine.~~

~~9. The PD-L1 bicyclic peptide mimetic of any one of claims 1-8, wherein X_5 is arginine.~~

~~10. The PD-L1 bicyclic peptide mimetic of any one of claims 1-9, wherein X_6 is selected from methionine, alanine, leucine and proline.~~

~~11. The PD-L1 bicyclic peptide mimetic of any one of claims 1-10, wherein X_6 is methionine.~~

~~12. The PD-L1 bicyclic peptide mimetic of any one of claims 1-11, wherein X_7 is selected from methionine, alanine, and proline.~~

~~13. The PD-L1 bicyclic peptide mimetic of any one of claims 1-12, wherein X_7 is methionine.~~

~~14. The PD-L1 bicyclic peptide mimetic of any one of claims 1-13, wherein X_7 is alanine.~~

~~15. The PD-L1 bicyclic peptide mimetic of any one of claims 1-14, wherein X_8 is selected from aspartic acid, alanine, glycine and valine.~~

~~16. The PD-L1 bicyclic peptide mimetic of any one of claims 1-15, wherein X_8 is aspartic acid.~~

~~17. The PD-L1 bicyclic peptide mimetic of any one of claims 1-16, wherein X_9 is selected from valine, alanine, glycine, methionine.~~

~~18. The PD-L1 bicyclic peptide mimetic of any one of claims 1-17, wherein X_9 is valine.~~

~~19. The PD-L1 bicyclic peptide mimetic of any one of claims 1-18, wherein X_{10} is selected from lysine, alanine, asparagine, and methionine.~~

~~20. The PD-L1 bicyclic peptide mimetic of any one of claims 1-19, wherein X_{10} is lysine.~~

~~21.~~2. The PD-L1 bicyclic peptide mimetic of ~~any one of claims 1-20~~ claim 1, wherein the peptide mimetic mimetic binds to importin, preferably preventing or disrupting the complex between PD-L1 and importin, preferably preventing or disrupting the complex between PD-L1 and importin.

~~22. (Cancelled) The PD-L1 bicyclic peptide mimetic of any one of claims 1-21, wherein the peptide mimetic prevents or disrupts the complex between PD-L1 and importin.~~

~~23.~~3. The PD-L1 bicyclic peptide mimetic of ~~any one of claims 1-22~~ claim 1 or claim 2, comprising the amino acid sequence: ACLTFIFCRLRKGRCMMDVKK [SEQ ID NO: 1].

~~24.~~4. The PD-L1 bicyclic peptide mimetic of any one of claims 1-~~23~~ 3 , wherein the molecular scaffold is 1,3,5-(tribroMoMethyl)benzene) or TBAB.

~~25.~~5. The PD-L1 bicyclic peptide mimetic of any one of claims 1-~~24~~ 4 , further comprising an N-terminal cell-penetrating peptide (for example, Myr).

~~26. The PD-L1 bicyclic peptide mimetic of claim 25, wherein the cell-penetrating peptide is Myr.~~

~~27.~~6. The PD-L1 bicyclic peptide mimetic of any one of claims 1-~~26~~ 5, wherein the modified derivative includes one or more modifications selected from: N-terminal and/or C-terminal modifications; replacement of one or more amino acid residues with one or more non-natural amino acid residues (such a replacement of one or more polar amino acids with one or more isosteric or isoelectronic amino acids; replacement or one or more hydrophobic amino acid residues with other non-natural isosteric or isoelectronic amino acids); addition of a spacer group; replacement of one or more oxidation resistant amino acid residues; replacement of one or more amino acid residues with an alanine, replacement of one or more L amino acid residues with one or more D-amino acid residues; N-alkylation of one or more aminide bonds within the bicyclic peptide ligand; replacement of one or more peptide bonds with a surrogate bond; peptide backbone length modification; substitution of the hydrogen on the α-carbon of one or more amino acid residues with another chemical group, and post-synthetic biorthogonal modification of amino acids such as cysteine, lysine, glutamate and tyrosine with suitable amine, thiol, carboxylic acid and phenol-reactive reagents.

~~28. The PD-L1 bicyclic peptide mimetic of any one of claims 1-27, wherein the modified derivative comprises an N-terminal modification, such as an N-terminal acetyl group.~~

~~29. The PD-L1 bicyclic peptide mimetic of any one of claims 1-28, wherein the modified derivative comprises a C-terminal modification, such as a C-terminal amide group.~~

~~30. The PD-L1 bicyclic peptide mimetic of any one of claims 1-29, wherein the modified derivative comprises replacement of one or more amino acid residues with one or more non-natural amino acid residues.~~

~~31.~~7. The PD-L1 bicyclic peptide mimetic of any one of claims 1-~~30~~ 6 , wherein the modified derivative comprises one or more D-amino acid (for example, wherein substantially all of the amino acids are D-amino acids).

~~32. The PD-L1 bicyclic peptide mimetic of any one of claims 1-31, wherein substantially of the amino acids are D-amino acids.~~

~~33.~~8. The PD-L1 bicyclic peptide mimetic of any one of claims 1 to ~~32~~ 7, wherein the peptide is formulated in a lipid nanoparticle.

~~34.~~9. The PD-L1 bicyclic peptide mimetic of any one of claims 1-~~28~~ 8, wherein the pharmaceutically acceptable salt is selected from a hydrochloride or acetate salt.

~~35.~~10. A pharmaceutical composition comprising the PD-L1 bicyclic peptide mimetic of any one of claims 1-~~29~~ 9, in combination with one or more excipients.

~~36.~~11. A method of reducing nuclear localization of PD-L1 in a PD-L1 overexpressing cell, the method comprising contacting the cell with a PD-L1 bicyclic peptide mimetic with the amino acid sequence of:

$$X_1C_1LX_2X_3IFC_2X_4LRKGX_5C_3X_6X_7X_8X_9KX_{10}$$

or a modified derivative, or pharmaceutically acceptable salt, thereof;

wherein:

C_1, C_2, and C_3 represent first, second and third cysteine residues, respectively;

X_1 is absent or alanine;

X_2 is selected from any small amino acid (optionally, threonine, glycine, serine, or alanine, and preferably threonine or alanine, and most preferably, threonine);

X_3 is selected from any amino acid (preferably phenylalanine or alanine, and most preferably, phenylalanine);

X_4 is selected from any amino acid (preferably arginine or alanine, and most preferably, arginine);

X_5 is selected from any amino acid (preferably arginine or alanine, and most preferably, arginine);

X_6 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, leucine, proline, glycine, isoleucine, phenylalanine, tryptophan, valine, ~~and~~ or norleucine, preferably methionine, alanine, leucine, or proline; and most preferably, methionine);

X_7 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, proline, leucine, glycine, isoleucine, phenylalanine, tryptophan, valine, and norleucine, preferably methionine, alanine or proline, and most preferably, methionine or alanine);

X_8 is selected from any amino acid (preferably, aspartic acid, alanine, glycine, or valine, and most preferably, aspartic acid);

X_9 is selected from any nonpolar/neutral amino acid (e.g., valine, alanine, glycine, methionine, leucine, proline, isoleucine, phenylalanine, tryptophan, ~~and~~or norleucine, preferably valine, alanine, glycine or methionine; and most preferably valine); and

X_{10} is selected from any amino acid (preferably lysine, alanine, asparagine, or methionine, and most preferably, lysine).

~~37. The method of claim 36, wherein X_2 is selected from threonine and alanine.~~

~~38. The method of claim 36 or claim 37, wherein X_2 is threonine.~~

~~39. The method of any one of claims 36-38, wherein X_3 is selected from phenylalanine and alanine.~~

~~40. The method of any one of claims 36-39, wherein X_3 is phenylalanine.~~

~~41. The method of any one of claims 36-40, wherein X_4 is selected from arginine and alanine.~~

~~42. The method of any one of claims 36-41, wherein X_4 is arginine.~~

~~43. The method of any one of claims 36-42, wherein X_5 is selected from arginine and alanine.~~

~~44. The method of any one of claims 36-43, wherein X_5 is arginine.~~

~~45. The method of any one of claims 36-44, wherein X_6 is selected from methionine, alanine, leucine and proline.~~

~~46. The method of any one of claims 36-45, wherein X_6 is methionine.~~

~~47. The method of any one of claims 36-46, wherein X_7 is selected from methionine, alanine, and proline.~~

~~48. The method of any one of claims 36-47, wherein X_7 is methionine.~~

~~49. The method of any one of claims 36-48, wherein X_7 is alanine.~~

~~50. The method of any one of claims 36-49, wherein X_8 is selected from aspartic acid, alanine, glycine and valine.~~

~~51. The method of any one of claims 36-50, wherein X_8 is aspartic acid.~~

~~52. The method of any one of claims 36-51, wherein X_9 is selected from valine, alanine, glycine, methionine.~~

~~53. The method of any one of claims 36-52, wherein X_9 is valine.~~

~~54. The method of any one of claims 36-53, wherein X_{10} is selected from lysine, alanine, asparagine, and methionine.~~

~~55. The method of any one of claims 36-54, wherein X_{10} is lysine.~~

~~56.~~12. The method of ~~any one of claims 36-55~~ claim 11, comprising the amino acid sequence: ACLTFIFCRLRKGRCMMDVKK [SEQ ID NO: 1].

~~57.~~13. The method of ~~any one of claims 36-56~~ claim 11 or claim 12, wherein the molecular scaffold is 1,3,5-(tribroMoMethyl)benzene) or TBAB.

~~58.~~14. The method of any one of claims ~~36-57~~11 to 13 , wherein the modified derivative comprises one or more D-amino acid (for example, all of the amino acids are D-amino acids) (for example, all of the amino acids are D-amino acids).

~~59. The method of any one of claims 36-58, wherein substantially of the amino acids are D-amino acids.~~

~~60.~~15. The method of any one of claims ~~36 to 59~~11 to 14 , wherein the peptide is formulated in a lipid nanoparticle.

~~61.~~16. The method of any one of claims ~~36-60~~11 to 15 , further comprising an N-terminal cell-penetrating peptide (for example, myristic acid).

~~62. The method of claim 61, wherein the cell-penetrating peptide is myristic acid.~~

~~63.~~17. A method of treating or preventing cancer in a subject, wherein the cancer comprises at least one PD-L1 overexpressing cell, comprising administering to the subject a PD-L1 bicyclic peptide mimetic of any one of claims 1~~-35~~ to 10.

~~64.~~18. The method of any one of claims ~~36-63~~11 to 17 , wherein the PD-L1 overexpressing cell is a cancer cell, cancer stem cell, or a non-cancer stem cell tumour cell.

~~65. The method of claim 64, wherein the PD-L1 overexpressing cell is a cancer stem cell tumour cell.~~

~~66.~~19. The method of any one of claims~~-63-65~~ 11 to 18, wherein the cancer is selected from breast, prostate, lung, bladder, pancreatic, colon, liver, or brain cancer, or melanoma, or retinoblastoma.

~~67.~~20. The method of any one of claims ~~36-66~~11 to 19 , further comprising administering at least one further cancer therapies (e.g., a chemotherapeutic agent).

~~68. The method of claim 67, wherein the further cancer therapy is a chemotherapeutic agent.~~

~~69. A composition comprising a PD-L1 bicyclic peptide mimetic with the amino acid sequence of:~~

~~$X_1C_1LX_2X_3IFC_2X_4LRKGX_5C_3X_6X_7X_8X_9KX_{10}$~~

~~or a modified derivative, or pharmaceutically acceptable salt, thereof;~~

~~wherein:~~

~~C_1, C_2, and C_3 represent first, second and third cysteine residues, respectively;~~

~~X_1 is absent or alanine;~~

~~X_2 is selected from any small amino acid (optionally, threonine, glycine, serine, or alanine)~~

~~X_3 is selected from any amino acid;~~

~~X_4 is selected from any amino acid;~~

X_5 is selected from any amino acid;

X_6 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, leucine, proline, glycine, isoleucine, phenylalanine, tryptophan, valine, and norleucine);

X_7 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, proline, leucine, glycine, isoleucine, phenylalanine, tryptophan, valine, and norleucine);

X_8 is selected from any amino acid;

X_9 is selected from any nonpolar/neutral amino acid (e.g., valine, alanine, glycine, methionine, leucine, proline, isoleucine, phenylalanine, tryptophan, and norleucine); and

X_{10} is selected from any amino acid;

for use in therapy.

70. A composition comprising a PD-L1 bicyclic peptide mimetic with the amino acid sequence of:

$$X_1C_1LX_2X_3IFC_2X_4LRKGX_5C_3X_6X_7X_8X_9KX_{10}$$

or a modified derivative, or pharmaceutically acceptable salt, thereof;

wherein:

C_1, C_2, and C_3 represent first, second and third cysteine residues, respectively;

X_1 is absent or alanine;

X_2 is selected from any small amino acid (optionally, threonine, glycine, serine, or alanine)

X_3 is selected from any amino acid;

X_4 is selected from any amino acid;

X_5 is selected from any amino acid;

X_6 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, leucine, proline, glycine, isoleucine, phenylalanine, tryptophan, valine, and norleucine);

X_7 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, proline, leucine, glycine, isoleucine, phenylalanine, tryptophan, valine, and norleucine);

X_8 is selected from any amino acid;

X_9 is selected from any nonpolar/neutral amino acid (e.g., valine, alanine, glycine, methionine, leucine, proline, isoleucine, phenylalanine, tryptophan, and norleucine); and

X_{10} is selected from any amino acid;

for use in the treatment of cancer.

71. Use of a composition comprising a PD-L1 bicyclic peptide mimetic with the amino acid sequence:

~~$X_1C_1LX_2X_3IFC_2X_4LRKGX_5C_3X_6X_7X_8X_9KX_{10}$~~

~~or a modified derivative, or pharmaceutically acceptable salt, thereof;~~

~~wherein:~~

~~C_1, C_2, and C_3 represent first, second and third cysteine residues, respectively;~~

~~X_1 is absent or alanine;~~

~~X_2 is selected from any small amino acid (optionally, threonine, glycine, serine, or alanine)~~

~~X_3 is selected from any amino acid;~~

~~X_4 is selected from any amino acid;~~

~~X_5 is selected from any amino acid;~~

~~X_6 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, leucine, proline, glycine, isoleucine, phenylalanine, tryptophan, valine, and norleucine);~~

~~X_7 is selected from any nonpolar/neutral amino acid (e.g., methionine, alanine, proline, leucine, glycine, isoleucine, phenylalanine, tryptophan, valine, and norleucine);~~

~~X_8 is selected from any amino acid;~~

~~X_9 is selected from any nonpolar/neutral amino acid (e.g., valine, alanine, glycine, methionine, leucine, proline, isoleucine, phenylalanine, tryptophan, and norleucine); and~~

~~X_{10} is selected from any amino acid;~~

~~in the manufacture of a medicament for the treatment of cancer.~~